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Key Points
• SRL and PDN often induce
disease stabilization or
objective responses in patients
with ECD.
• The phosphorylated forms of
mTOR and of its downstream
kinase p70S6K are strongly
expressed in infiltrating
histiocytes.
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, to whose
pathogenesis neoplastic and immune-mediated mechanisms contribute. Mammalian
target of rapamycin (mTOR)-inhibitors have antiproliferative and immunosuppressive
properties.We tested in this study, theefficacyandsafetyof themTOR-inhibitor sirolimus
(SRL) plus prednisone (PDN) in patients with ECD. PDN was given initially at 0.75 mg/kg
perday, tapered to5 to2.5mgperdaybymonth6.TargetSRLblood levelswere8 to12ng/mL.
Treatment was continued for at least 24 months in patients who showed disease stabi-
lization or improvement. Ten patients were enrolled; 8 achieved stable disease or objective
responses, whereas 2 had disease progression. Responses were mainly observed at the
followingsites: retroperitoneum in5/8patients (62.5%), cardiovascular in 3/4 (75%), bone in
3/9 (33.3%), and central nervous system (CNS) in 1/3 (33.3%). The median follow-up was
29 months (interquartile range, 16.5-74.5); 2 patients died of progressive CNS disease and
small-cell lung cancer, respectively. Treatment-related toxicity was mild. Using immuno-
histochemistry and immunofluorescenceonECDbiopsies,wedetected expression in foamyhistiocytesof the phosphorylated formsof
mTOR and of its downstream kinase p70S6K, which indicated mTOR pathway activation. In conclusion, SRL and PDN often induce
objective responses or disease stabilization and may represent a valid treatment of ECD. The trial is registered at the Australia-New
Zealand Clinical Trial Registry as #ACTRN12613001321730. (Blood. 2015;126(10):1163-1171)
Introduction
Erdheim-Chester disease (ECD) is an extremely rare and often life-
threatening form of non-Langerhans cell histiocytosis, characterized
by tissue inﬁltration of CD681CD1a2 “foamy” histiocytes. To date,
only ;550 cases of ECD have been reported in the literature.1 The
most frequent manifestations of ECD include symmetric long bone
osteosclerosis, retroperitoneal inﬁltration (peri-aortic and peri-renal
ﬁbrosis), andcardiovascular lesions (pericarditis,myocardial inﬁltra-
tion, and peri-aortic sheathing); the central nervous system (CNS),
the retro-orbital space, the skin, and various endocrine axes are also
frequently affected.2,3
The pathogenesis of ECD is still unclear. Initial studies investi-
gating the clonal nature of the inﬁltrating histiocytes yielded conﬂicting
results4,5; however, the recent observation that ;50% of ECD cases
harbor theV600Emutation of theBRAFproto-oncogene,6 togetherwith
other reports showing NRAS mutations,7,8 indicate that ECD can be
clonally driven. Immune-mediatedmechanisms are also of pathogenetic
importance. ECD histiocytes show intense expression of chemokines
and their receptors and produce pro-inﬂammatory cytokines9,10; the
serum cytokine proﬁle demonstrates T helper-1 polarization, with
upregulation of interleukin (IL)-12, interferon (IFN)-g inducible
protein-10, and monocyte chemotactic protein-1.11
Different therapeutic approaches have been used for ECD.
IFN-a is considered the ﬁrst-line therapy and is thought to induce
immune-mediated histiocyte killing and terminal differentiation
of immature histiocytes. However, IFN-a is often ineffective and
poorly tolerated.3 The BRAFV600E inhibitor vemurafenib proved
markedly effective in BRAFV600E-mutated cases,12,13 but the
BRAFV600E mutation is either absent or not detected in ;50% of
ECD patients,14 therefore therapeutic alternatives are needed.
Other treatments include antineoplastic drugs (eg, cladribine
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and imatinib mesylate)15 and immunosuppressive agents such as
IL-1–receptor- and tumor necrosis factor-a–blocking antibodies,16,17
but these drugshaveonlybeen tested in single casesor small caseseries.
The mammalian target of rapamycin (mTOR) integrates extracel-
lular and intracellular signals to regulate cell growth, proliferation and
apoptosis, and several metabolic processes such as protein and lipid
synthesis. mTOR also modulates immune responses, as it promotes
differentiation and activation of B cells, T cells, and antigen-presenting
cells.18 Aberrant mTOR activation is found in neoplastic and inﬂam-
matory conditions, so mTOR inhibitors (given their antiproliferative
and immunosuppressive properties) are now used in different settings,
including malignancies19 and the prevention of allograft rejection.20
Interestingly, a recent study showed that some (although only;11%)
ECDpatients harborPIK3CAmutations,which lead tomTORpathway
activation.14
On the basis of the above considerations, particularly the dual
neoplastic-inﬂammatory nature of ECD, we used the mTOR inhibitor
sirolimus (SRL) in combination with prednisone (PDN) for patients
withmultisystemic ECD.We report here the results of our trial, which
tested the efﬁcacy and safety of this approach in 10 consecutive ECD
patients, and also provide preliminary evidence of mTOR pathway
activation in ECD lesions.
Methods
Patients
Patient #1, treated empirically with SRL1PDN from June 2005, represented our
index case. Encouraged by his clinical response, which persisted after 2 years of
treatment, we designed this open-label trial. We enrolled all patients meeting the
eligibility criteria, referred to the Nephrology Unit of Parma University Hospital
between December 2007 and June 2013. Key inclusion criteria were a diagnosis
of multisystemic ECD based on Veyssier-Belot criteria21 and an age of 18 to
75 years. We enrolled both newly diagnosed, untreated patients, as well as
those patients who proved refractory to previous treatments. Key exclusion
criteria were concurrent neoplasms or other forms of histiocytosis, serious
infections, uncontrolled diabetes, estimated glomerularﬁltration rate,30mL/min,
proteinuria.1 g/24 h, and recent major surgery.
The patients signed an informed consent form. The study was performed
in accordance with the Declaration of Helsinki and was approved by the
Parma Ethical Committee.
Treatment protocol and assessment of response
At study entry, the patients underwent physical examination and routine labo-
ratory tests, including C-reactive protein levels and endocrine tests (thyrotropin,
FT3, FT4, prolactin, luteinizing hormone, follicle-stimulating hormone, testos-
terone, estradiol, cortisol, and adrenocorticotropic hormone).We also performed
long-bone radiographs, 99Tc-bone scintigraphy, high-resolution chest computed
tomography (CT), contrast-enhanced abdominal CT or magnetic resonance
imaging (MRI), brain MRI, and echocardiography. As 18F-ﬂuorodeoxyglucose
(18F-FDG)-positron emission tomography (PET) became available for this
indication at Parma University Hospital in 2009, it was performed in only
7 patients. Likewise, cardiac MRI became routinely available at our center in
2010, thus it was performed in only 5 patients.
All patients received PDN and SRL. PDNwas given orally at a single daily
dose of 0.75mg/kg per day formonth 1, 0.5mg/kg per day formonth 2, 0.25mg/kg
per day for months 3 to 4, and 0.125 mg/kg per day for months 5 to 6. After
month 6, it was tapered to a maintenance dose of 2.5 to 5 mg per day. SRLwas
given orally at an initial dose of 2 mg/day (single daily dose), and subsequently
titrated to reach blood levels of 8 to 12 ng/mL; this blood level rangewas chosen
based on the experience accumulated in solid organ transplantation and in renal
angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.20,22
Blood SRL levels were checked fortnightly during the ﬁrst 2 months and
subsequently every 1 to 2months. The target SRL range remained unchangedT
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throughout the study. Proton-pump inhibitors, calcium, vitaminD, and statins
were also routinely prescribed.
Treatment was conducted until the ﬁrst assessment of response (month 6); if
disease stabilization or remission was achieved, treatment was continued until
month 24. In case of disease progression, it was withdrawn and choice of the
alternative therapywas left at the discretion of the treating clinician. After month
24, the physician was free to continue or withdraw treatment based on patient’s
status and treatment tolerability.
Follow-up visits, which included clinical and laboratory examinations, were
done every 1 to 2months during the ﬁrst year and every 3 to 6months thereafter.
Complete disease re-stagingwas performed atmonth 6, 12, and every 12months
thereafter; in addition, patients were scanned as soon as new or worsening
symptoms appeared. Responses were assessed clinically and radiologically,
using the same imagingmodalities performed at baseline.Whole-bodyPET-CT
was repeated only in patients with pathologic uptake at baseline.
Objective responses were deﬁned on CT or MRI ﬁndings as complete or
partial responses (PRs), stable disease (SD), and progressive disease (PD),
generally following the RECIST criteria (version 1.0).23 Brieﬂy, complete
responses (CRs) indicated the disappearance of a given lesion, and PRs a
decline of at least 30% in the sum of the longest lesion diameters; SD was
deﬁned as neither PR nor PD, and PD as an increase of at least 20% in the sum
of lesion diameters or appearance of new lesions. For speciﬁc lesions such as
peri-aortic ﬁbrosis, the maximal thickness of the tissue was recorded at infra-
renal aorta and common iliac artery levels,24 and the average of these measures
was calculated. For nonmeasurable lesions (eg, bone inﬁltration), we followed
the RECIST 1.0 grading as CR, incomplete response/SD, and PD.
On 18F-FDG-PET, the response was graded on the changes of themaximum
standardized uptake value (SUVmax), generally following thePERCIST criteria
25;
patients were thus categorized as having complete or partial metabolic responses
(PMRs) (complete resolution or decline of at least 30% of 18F-FDG uptake,
respectively), stable metabolic disease (neither PMR nor progressive metabolic
disease), or progressivemetabolic disease (increase of at least 30% in target lesion
activity or appearance of new lesions).
Treatment-related toxicity was assessed at each visit by a checklist of
standardized items,measurement of blood pressure and bodyweight, and routine
laboratory tests. Adverse events (AEs) were graded following the National
Cancer Institute CommonTerminologyCriteria for Adverse Events, version 4.26
Biopsy examination and analysis of mTOR pathway activation
Tissue biopsies were centrally reviewed by a pathologist with expertise in soft-
tissue tumors (D.C.); routine stainings and immunohistochemical analysis of
CD68 and CD1a expression were performed. BRAFV600E mutation was assessed
on the available biopsies.Details on histologic and immunohistochemical analyses
and BRAFV600E testing are reported in supplemental Methods on the BloodWeb
site. Where sufﬁcient biopsy tissue was available, we also searched for recurrent
mutations in the NRAS, KRAS, and PIK3CA genes (supplemental Methods).
To assesswhethermTORpathway is active in ECD lesions, and in particular
in ECD histiocytes, we assessed the expression of phospho-p70S6K, phospho-
mTOR, andCD68using immunohistochemistry (IHC)and immunoﬂuorescence
(supplemental Methods).
Statistical analysis
Data are presented asmedian (interquartile range [IQR]); survival was estimated
using the Kaplan–Meier method. All analyses were done using SPSS version
20.0 (SPSS Inc., Chicago, IL).
Figure 1. Response to treatment assessed by different imaging modalities. (A)
Abdominal CT performed before treatment and (B) after 4 years of SRL and PDN
treatment in patient #2. The scans show marked shrinkage of peri-renal (arrows) and
peri-aortic fibrosis (arrowhead). (C) Cardiac MRI (T2-weighted, fat-saturation sequence,
sagittal view) performed before treatment and (D) after 12 months of treatment with SRL
and PDN in patient #10. The scans show neither recurrence of pericardial effusion
(arrow) (the patient had also undergone pericardiocentesis) nor signs of pericardial
infiltration. (E) 18F-FDG PET-CT performed before and (F) after 12 months of treatment
with SRL and PDN in patient #10. The scans (axial view) show disappearance of
18F-FDG uptake at the thoracic aorta level (aortic arch) (arrow).
Figure 2. Response to treatment in the long bones assessed by bone scintigraphy.
(A) Whole-body 99Tc-bone scintigraphy performed before treatment and (B) after 12 months
of treatment with SRL and PDN in patient #5. The scans show a significant reduction in
tracer uptake especially in long bones such as the tibias (arrows) and the femurs.
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Results
After our index case (patient #1), we screened 11 consecutive patients,
of whom 2 did not meet the eligibility criteria; the remaining 9 were
enrolled. The results presented here refer to the whole series of 10
patients, including the index case; patient enrollment and follow-up is
schematically described in the ﬂow-chart (supplemental Figure 1). All
but 1 patient (patient #6) had biopsy-proven ECD; in the nonbiopsy
proven case, the diagnosis was based on typical bone scintigraphy and
long-bone radiograph ﬁndings, together with the presence of CNS
lesions compatible with ECD. Three patients were refractory to
previous treatments, whereas 7were newly diagnosed and untreated.
The main patient characteristics are described in Table 1.27 Long-
bone involvementwas found in9 patients, althoughonly 4 complained
of bone pain. Retroperitoneal involvement was also common: most
patients showed peri-aortic, peri-renal, and peri-ureteral ﬁbrosis
causing hydronephrosis, which required ureteral double-J stent
placement in 4 cases. Notably, in 4 patients, peri-aortic ﬁbrosis also
involved the mesentery; 2 of these patients developed repeat bowel
obstructions requiring surgery.Cardiac and thoracic aorta involvement
was found in 4 cases, although it must be acknowledged that only 5
patients were studied using cardiac MRI (the remaining with echocar-
diography); 2 patients had pericarditis with massive pericardial effu-
sion, with 1 patient developing tamponade. CNS involvement was
detected in 3 patients: 1 had a large hemispheric mass (that was
surgically excised) and small cortical and brainstem nodules, 1 had
diffuse cortical-subcortical nodules, and 1 a very severe involvement
of the brainstem and the cerebellar peduncles together with supra-
tentorial lesions. Interstitial lung disease was radiologically detected
in 3 patients, none of whomwas symptomatic. Other manifestations,
including endocrine abnormalities, skin lesions, exophthalmos, and
soft-tissue masses were also found (Table 1). Finally, most patients
had systemic symptoms: in particular, 5 patients (patients #1, 2, 3, 8,
and 10) complained of fatigue, 2 (patients #3 and #8) had fever, 2 had
weight loss (patients #6 and #8), and 1 (patient #8) developed severe
cachexia, aggravated by intestinal obstruction episodes.
The BRAFV600E mutation was detected in 3/6 patients in whom it
was assessed; nomutations inNRAS,KRAS, orPKI3CAwere detected
in the tested patients (Table 1).
All patients received SRL and PDN following the treatment
schedule, with no signiﬁcant protocol deviations. Objective responses
are reported in Table 2. Eight patients showed either disease stabi-
lization or partial/CRs, whereas 2 patients had disease progression;
of these, patient #6 had rapidly progressive CNS lesions, refused to
take IFN-a and switched to IMmethotrexate but resumed SRL after
1 month because of poor methotrexate tolerability. He eventually
died after 11 months of treatment. The second patient with PD
(patient #8) had SD atmonths 6 to 12, but later progressed at cardiac
and retroperitoneal levels; she switched to vemurafenib (at month
25) as shewas found to beBRAFV600E-positive and later experienced
disease stabilization.
The remaining 8 patients showed PRs of at least one involved site.
Retroperitoneal lesions regressed partially in 4/8 cases and completely
in 1/8 (Figure 1 and supplemental Figure 2): at last follow-up, only 2
patients had double-J ureteral stents, and the patient with repeat bowel
obstructions (patient #1) no longer developed such complications.
Cardiovascular lesions improved in3/4 cases: the 2 patientswith severe
pericarditis (one of whom was previously described28) underwent
pericardiocentesis and remained free of pericardial effusion over the
entire follow-up (Figure 1). Bone disease usually remained stable,
although an improvement at 99Tc-scintigraphywas observed in 3 cases
(Figure 2). CNS lesions progressed in patient #6 and stabilized in
patient #3, whereas in patient #7 there was no recurrence of the
surgically excised brain mass, and the remaining nodules showed
partial regression (supplemental Figure 3). Lung involvement stabilized
in all cases. The outcome of the remaining disease manifestations is
reported in Table 2. Systemic symptoms improved in most patients; the
only patient who experienced persistent systemic manifestations was
patient #8. C-reactive protein levels also tended to decrease over time
(supplemental Figure 4).
PET-CT was positive at baseline (especially at the bone, vascular,
soft-tissue, and retroperitoneal levels) in 5/7 patients studied
(Table 2): of these, 1 patient achieved a CMR (Figure 1), 1 a PMR,
1 SD, 1 was lost to follow-up before follow-up PET-CT was
performed, and 1 did not repeat PET-CT because of overt clinical
progression.
No clinical or laboratory parameters predicted response to therapy.
BRAFV600Emutation, detected in3/6patients tested, alsodidnot predict
particular response patterns.The median follow-up from the start of
treatment was 28.5 months (IQR, 16.5-74.5). Two patients died, 1
(patient #6) of progressive CNS disease and the other (patient #5) of
metastatic small-cell lung cancer, which developed while ECD was
clinically silent; in this patient, SRL and PDN were withdrawn after
cancer diagnosis (atmonth 15), he received chemotherapy (etoposide1
cysplatin) and died 10 months later from cancer-related complications
(survival analysis of the whole cohort is shown in supplemental
Figure 5).
Treatment was generally well tolerated; the main AEs are reported
in Table 3. Patient #4 withdrew SRL for 1 month for infectious
panniculitis, whereas patient #9withdrew it for 3months for interstitial
pneumonitis and then resumed it at a lower dose. At last follow-up,
all patients were on SRL and PDN except for patient #5 who had
developed small-cell lung cancer and patient #8 who had switched
to vemurafenib; in all cases, the maintenance PDN dose was 2.5 to
5 mg/day.
To investigatewhether themTORpathway is active inECDlesions,
we used IHC,which revealed a diffuse expression of phospho-p70S6K
and phospho-mTOR in foamy ECD histiocytes (Figure 3 and supple-
mental Figure 6). Confocal microscopy showed co-localization of
phospho-p70S6K and CD68 (Figure 4), and of phospho-mTOR and
CD68 (Figure 4), thus conﬁrming that histiocytes were phospho-
p70S6K- and phospho-mTOR–positive. Isotype control staining is
shown in supplemental Figure 7.
Table 3. AEs occurred during treatment with SRL and PDN
Patient # AEs
1 Hypertension (grade 2)
2 Worsened (preexisting) hyper-triglyceridemia (grade 3) and cushingoid
changes (grade 1)
3 Cushingoid changes (grade 1)
4 Worsened (preexisting) type 2 diabetes (grade 2), left leg panniculitis
(grade 3), and acute coronary syndrome (grade 4) requiring
percutaneous angioplasty
5 Worsened (preexisting) type 2 diabetes (grade 2), bilateral leg edema
(grade 2), and cushingoid changes (grade 2)
6 Cushingoid changes (grade 1)
7 Hyper-cholesterolemia (grade 1) and hyper-triglyceridemia (grade 2)
8 Hyper-triglyceridemia (grade 2), cataract (grade 2), and abdominal aorta
thrombosis (grade 3)
9 Interstitial pneumonitis (grade 2)
10 Hyper-cholesterolemia (grade 1) and hyper-triglyceridemia (grade 2)
AEs were categorized according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events, version 4.24
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Discussion
ECD often has a progressive, life-threatening course. IFN-a has sub-
stantially improved the prognosis of ECD patients, but this treatment is
poorly tolerated and often ineffective on cardiac and CNS lesions,
although studies using high IFN-a doses showed cardiac and CNS
responses.2,27,29 The recent introduction of the BRAFV600E-inhibitor
vemurafenib offers an exciting perspective for BRAFV600E-mutated
patients; however, the experience with vemurafenib treatment is still
limited12,13,30 and no targeted therapy is available for BRAF-wild-type
patients. Therefore, alternative treatments are needed for ECD. In this
trial, we show that the combination of SRL and PDN generally leads to
stabilization or improvement of ECD and induces objective responses
in a substantial proportion of patients.
The experience with this therapeutic regimen began with our index
case, that we empirically treated with SRL and PDN based on the
assumption that ECD has an inﬂammatory-neoplastic nature. Because
he responded brilliantly despite an aggressive clinical presentation, we
decided to design this trial. All the enrolled patients hadmultisystemic
involvement and their clinical manifestations were comparable to
those reported in other cohorts.2,27 Bone disease, affecting the long
bones and in some cases also the facial bones was extremely common
(90% of the cases), as well as retroperitoneal involvement (80% of
the cases) that caused severe complications such as obstructive
uropathy and bowel obstruction. Cardiac and large-vessel disease
was detected in 40% of the cases, whereas CNS lesions in only
30%, this manifestation being slightly less frequent than in other
series.2,27
Of our 10 patients, 8 had objective responses or disease stabiliza-
tion, whereas 2 had disease progression. Responses varied at the dif-
ferent sites. We observed signiﬁcant responses at the retroperitoneal
level, with frequent shrinkage of peri-renal and peri-ureteral masses.
Patients presenting with severe pericarditis also had an excellent
outcome, as they did not show any recurrence of pericardial effusion
after pericardiocentesis; however, the course of pericarditis in ECD
is still uncertain and it is unknown how often it recurs after peri-
cardiocentesis, thus it is not possible to conclude that the remission of
pericarditis was entirely due to our treatment. Responses were hetero-
geneous at theCNS level,whereas theyweremarginal or absent at other
sites, such as the endocrine system and the bone; however, it must be
acknowledged that endocrine abnormalities (eg, diabetes insipidus)
in ECD rarely improve,29 and that bone disease does not signiﬁcantly
impact patient prognosis. Inparallelwithobjective response assessment
by CT/MRI, we also performedwhole-body PET in a fraction of cases;
in somepatients, we observed partial orCMRswhile the corresponding
Figure 3. Immunohistochemical analysis of phospho-mTOR and phospho-p70S6K in ECD lesions. (A-C) Two ECD cases located in the skin and (D-F) bone, where the
lesional CD68-KP1–positive histiocytes (B,E) show immunoreaction for phospho-p70S6K (C,F). In (D-F), the arrowhead indicates some elongated histiocytes, whose shape
results from their encasement by abundant sclerotic fibrous tissue. An additional case of ECD involving the skin (G-I) with CD68-KP1–positive histiocytes (H), which also react
with an anti–phospho-mTOR antibody (I) is shown. Original magnification: (A-I), 320; insets in (D-F), 340. HE, hematoxylin and eosin.
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lesions were still unchanged on CT/MRI, which further supports the
efﬁcacy of our treatment.
Overall survival is signiﬁcantly reduced in ECD; per the article
by Veyssier-Belot et al, 35 (60%) of the 58 patients whose data were
available died, with a mean survival of 19.2 months.21 A series
published in 2004 also documented a mortality rate of 60%.31 A
more recent analysis of patients largely treated with IFN-a yielded
amortality of 26%.2 Considering these data, our 20%mortality (after
a median follow-up of 29 months [IQR, 16.5-74.5] from the start of
treatment) appears to be one of themost favorable outcomes reported
in the literature. Notably, our therapeutic regimen was also well
tolerated, with most patients being able to continue it chronically for
several years. This aspect is crucial, since other approaches such as
IFN-a, chemotherapy, or even the BRAFV600E-inhibitor vemurafe-
nib can be associatedwith severe side effects that often preclude their
long-term use. Overall, we believe that our treatment regimen might
be a feasible option forBRAFV600E-negative patientswhohave contrain-
dications to IFN-a or who have failed IFN-a; whether our regimen can
be considered ﬁrst-line treatment of BRAFV600E-negative cases cannot
yet be determined, and further data are needed.
The mechanisms through which our therapy induces responses are
a point ofmajor interest. It is conceivable that responses are largely due
toSRL, as it is nowknown that glucocorticoids are generally ineffective
in ECD, except for regimens using high doses that induce improve-
ment of selected manifestations such as exophthalmos.1 The relative
inefﬁcacy of glucocorticoids was not clear at the time we designed the
trial, andwe decided not to change our schedule; additionally,we could
not exclude a synergistic effect of SRL and PDN. Future studies based
on mTOR-inhibitors given as monotherapy are feasible and could
prove useful to address this point.
mTOR is an important regulator of cell growth, proliferation, and
apoptosis. In our exploratory analysis, we found signs of activation of
themTORpathway inECD lesions: the phosphorylated formofmTOR
was intensely expressed on immunohistochemical and immunoﬂuo-
rescence analysis of ECDbiopsies, and sowas the phosphorylated form
of p70S6K, a kinase downstream of mTOR.32 Interestingly, phospho-
mTOR and phospho-p70S6K were particularly expressed by CD681
foamy histiocytes. mTOR signaling proceeds via two different com-
plexes:mTOR-complex 1 (mTORC1) andmTORC2,wheremTORC1
is believed to be more rapamycin-sensitive.18 Phospho-p70S6K ex-
pression denotes a clear involvement of mTORC1. Multiple factors
may contribute to mTOR activation: in a recent study, mutations in
NRAS and PIK3CA, which activate mTOR, were detected in 4% and
11% of ECD patients, respectively.14 Probably due to the low number
of tested cases, thesemutationswere negative in our patients. However,
othermechanisms involving solublemediators or cell surface receptors
that ultimately switch on the mTOR pathway may be involved and
warrant investigation.
Our clinical results aremainly limitedby the small size of our patient
cohort; however, ECD is extremely rare and our trial is so far the largest
Figure 4. Confocal microscopy analysis of phospho-mTOR and phospho-p70S6K in ECD lesions. The same cases as those shown in Figure 3 with immunoreaction for
CD68-KP1 (A,D,G), phospho-p70S6K (B,E), phospho-mTOR (H), and relevant merged images (C,F,I). Original magnification: (A-I), 363.
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prospective investigation in this disease. Additionally, we assessed the
major gene mutations identiﬁed in ECD in only a fraction of cases, but
these ﬁndings are very recent and tissue specimens for molecular anal-
ysis were often insufﬁcient in our patients.
In conclusion, treatment with SRL and PDN often induces disease
stabilization or objective responses in ECD, and is well tolerated;
therefore, it represents a valid alternative for patients not candidate to
targeted therapies or for thosewho are intolerant or refractory to IFN-a.
ThemTORpathway appears to be active inECD lesions, particularly in
ECD histiocytes.
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